The association of serum nesfatin-1 and ghrelin levels with metabolic syndrome in patients with schizophrenia

ÜNAL K., Yuksel R. N., Turban T., Sezer S., Yaylaci E. T.

PSYCHIATRY RESEARCH, vol.261, pp.45-49, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 261
  • Publication Date: 2018
  • Doi Number: 10.1016/j.psychres.2017.12.041
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus
  • Page Numbers: pp.45-49
  • Keywords: Schizophrenia, Nesfatin-1, Ghrelin, Metabolic Syndrome, Schizophrenia treatment, FOOD-INTAKE, DIABETES-MELLITUS, 1ST EPISODE, LEPTIN, DISTURBANCES, ADIPONECTIN, MECHANISMS, INSULIN, BLOOD
  • Gazi University Affiliated: No


Nesfatin-1 and ghrelin are two hormones which has opposite effects and play role in food intake. This study was planned on the idea that both metabolic syndrome and psychiatric disorders are associated with nesfatin-1 and ghrelin. In this study, it was aimed to investigate the levels of ghrelin and nesfatin-1 in patients with schizophrenia, by taking confounding factor as the metabolic syndrome (MS). 55 patients with schizophrenia and 33 healthy controls were included in the study 11 out of the 55 patients (%20) has MS. Serum ghrelin and nesfatin-1 levels of schizophrenia patients with MS have been compared with both healthy controls and schizophrenia patients without MS. Patients with schizophrenia had significantly higher serum nesfatin-1 levels compared to healthy controls. But serum ghrelin levels was not different in both groups. Serum nesfatin-1 concentrations were significantly higher in the schizophrenia patients with MS (10.51-350.8 pg/ml) with respect to the healthy control group (4.86-68.91 pg/ml). There was no significant statistical difference between the three groups in terms of ghrelin levels. Our findings suggests that, MS presence also contributed to significantly high levels of nesfatin-1 level. Nesfatin-1 may have a part in a novel studies regarding the treatment of schizophrenia and its metabolic effects.